Literature DB >> 32671805

Long-term mortality and costs following use of Impella® for mechanical circulatory support: a population-based cohort study.

Shannon M Fernando1,2, Danial Qureshi3,4,5, Peter Tanuseputro3,4,5,6,7, Robert Talarico3,4, Benjamin Hibbert8, Rebecca Mathew9,8, Bram Rochwerg10,11, Emilie P Belley-Côté10,12,13, Eddy Fan14,15, Alain Combes16,17, Daniel Brodie18,19, Matthieu Schmidt16,17, Trevor Simard8, Pietro Di Santo8, Kwadwo Kyeremanteng9,4,7,20.   

Abstract

PURPOSE: The Impella® device is a form of mechanical circulatory support (MCS) used in critically ill adults with cardiogenic shock. We sought to evaluate short- and long-term outcomes following the use of Impella, including mortality, healthcare utilization, and costs.
METHODS: Population-based, retrospective cohort study of adult patients (≥ 16 yr) receiving Impella in Ontario, Canada (1 April 2012-31March 2019). We captured outcomes through linkage to health administrative databases. The primary outcome was mortality during hospitalization. Secondary outcomes included mortality at 30 days, 90 days, and one year following Impella insertion. We analyzed health system costs in Canadian dollars in the year following the date of the index admission, including the costs of inpatient admission.
RESULTS: We included 162 patients. Mean (standard deviation) age was 59.2 (14.5) yr, and 73.5% of patients were male. Median [interquartile range (IQR)] time to Impella insertion from date of hospital admission was 2 [1-9] days. In-hospital mortality was 56.8%, and a significant proportion of patients were bridged to a ventricular assist device (67.9%). Mortality at one year was 61.7%. Among hospital survivors, only 38.6% were discharged home independently. Median [IQR] total cost in the year following admission among all patients was $88,397 [32,718-225,628], of which $66,529 [22,789-183,165] was attributed to inpatient care.
CONCLUSIONS: In-hospital mortality among patients with cardiogenic shock receiving Impella is high, but with minimal increase at one year. While Impella patients accrued substantial costs, these largely reflected inpatient costs, and not costs incurred following hospital discharge.

Entities:  

Keywords:  Impella; cardiogenic shock; health services; mechanical circulatory support

Year:  2020        PMID: 32671805     DOI: 10.1007/s12630-020-01755-9

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  10 in total

1.  Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative.

Authors:  Mir B Basir; Navin K Kapur; Kirit Patel; Murad A Salam; Theodore Schreiber; Amir Kaki; Ivan Hanson; Steve Almany; Steve Timmis; Simon Dixon; Brian Kolski; Josh Todd; Shaun Senter; Steven Marso; David Lasorda; Charles Wilkins; Thomas Lalonde; Antonious Attallah; Timothy Larkin; Allison Dupont; Jeffrey Marshall; Nainesh Patel; Tjuan Overly; Michael Green; Behnam Tehrani; Alexander G Truesdell; Rahul Sharma; Yasir Akhtar; Thomas McRae; Brian O'Neill; John Finley; Ayaz Rahman; Malcolm Foster; Raza Askari; Andrew Goldsweig; Scott Martin; Aditya Bharadwaj; Matheen Khuddus; Christopher Caputo; Denes Korpas; Ian Cawich; David McAllister; Nimrod Blank; M Chadi Alraies; Ruth Fisher; Akshay Khandelwal; Khaldoon Alaswad; Alejandro Lemor; Tyrell Johnson; Michael Hacala; William W O'Neill
Journal:  Catheter Cardiovasc Interv       Date:  2019-04-25       Impact factor: 2.692

2.  Clinical Indications of IMPELLA Short-Term Mechanical Circulatory Support in a Tertiary Centre.

Authors:  María Monteagudo Vela; Andre Simon; Fernando Riesgo Gil; Alex Rosenberg; Miles Dalby; Tito Kabir; Diana García Saez; Vasileios Panoulas
Journal:  Cardiovasc Revasc Med       Date:  2019-12-06

3.  Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial.

Authors:  Holger Thiele; Uwe Zeymer; Nathalie Thelemann; Franz-Josef Neumann; Jörg Hausleiter; Mohamed Abdel-Wahab; Roza Meyer-Saraei; Georg Fuernau; Ingo Eitel; Rainer Hambrecht; Michael Böhm; Karl Werdan; Stephan B Felix; Marcus Hennersdorf; Steffen Schneider; Taoufik Ouarrak; Steffen Desch; Suzanne de Waha-Thiele
Journal:  Circulation       Date:  2018-11-11       Impact factor: 29.690

4.  Acute kidney injury treated with renal replacement therapy and 5-year mortality after myocardial infarction-related cardiogenic shock: a nationwide population-based cohort study.

Authors:  Marie Dam Lauridsen; Henrik Gammelager; Morten Schmidt; Thomas Bøjer Rasmussen; Richard E Shaw; Hans Erik Bøtker; Henrik Toft Sørensen; Christian Fynbo Christiansen
Journal:  Crit Care       Date:  2015-12-30       Impact factor: 9.097

5.  Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.

Authors:  Emma J M Grigor; Dean A Fergusson; Fatima Haggar; Natasha Kekre; Harold Atkins; Risa Shorr; Robert A Holt; Brian Hutton; Tim Ramsay; Matthew Seftel; Derek Jonker; Mads Daugaard; Kednapa Thavorn; Justin Presseau; Manoj M Lalu
Journal:  BMJ Open       Date:  2017-12-29       Impact factor: 2.692

6.  Long-term survival and costs following extracorporeal membrane oxygenation in critically ill children-a population-based cohort study.

Authors:  Shannon M Fernando; Danial Qureshi; Peter Tanuseputro; Sonny Dhanani; Anne-Marie Guerguerian; Sam D Shemie; Robert Talarico; Eddy Fan; Laveena Munshi; Bram Rochwerg; Damon C Scales; Daniel Brodie; Kednapa Thavorn; Kwadwo Kyeremanteng
Journal:  Crit Care       Date:  2020-04-06       Impact factor: 9.097

Review 7.  Prognosis Research Strategy (PROGRESS) 3: prognostic model research.

Authors:  Ewout W Steyerberg; Karel G M Moons; Danielle A van der Windt; Jill A Hayden; Pablo Perel; Sara Schroter; Richard D Riley; Harry Hemingway; Douglas G Altman
Journal:  PLoS Med       Date:  2013-02-05       Impact factor: 11.069

8.  Long-term outcomes and healthcare utilization following critical illness--a population-based study.

Authors:  A D Hill; R A Fowler; R Pinto; M S Herridge; B H Cuthbertson; D C Scales
Journal:  Crit Care       Date:  2016-03-31       Impact factor: 9.097

9.  Characteristics, Outcomes, and Cost Patterns of High-Cost Patients in the Intensive Care Unit.

Authors:  Peter M Reardon; Shannon M Fernando; Sasha Van Katwyk; Kednapa Thavorn; Daniel Kobewka; Peter Tanuseputro; Erin Rosenberg; Cynthia Wan; Brandi Vanderspank-Wright; Dalibor Kubelik; Rose Anne Devlin; Christopher Klinger; Kwadwo Kyeremanteng
Journal:  Crit Care Res Pract       Date:  2018-09-02
  10 in total
  1 in total

Review 1.  Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis.

Authors:  Benjamin Hibbert; Bram Rochwerg; Shannon M Fernando; Rebecca Mathew; Behnam Sadeghirad; Daniel Brodie; Emilie P Belley-Côté; Holger Thiele; Sean van Diepen; Eddy Fan; Pietro Di Santo; Trevor Simard; Juan J Russo; Alexandre Tran; Bruno Lévy; Alain Combes
Journal:  Can J Anaesth       Date:  2022-10-04       Impact factor: 6.713

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.